Discovery & Exploratory

The Global Antibiotic Research and Development’s (GARDP) discovery and exploratory research programme is screening chemical compound libraries for activity against the drug-resistant priority pathogens that urgently require new treatments.

Discovery and exploratory research to find novel antibiotics is critical to addressing drug-resistant infections. Using new science and technological advances, GARDP is also working on asset evaluation and development in order to repurpose under-used or forgotten compounds alone or in combination.

“Eisai strongly identifies with GARDP’s efforts to discover novel antibiotics to treat drug-resistant infections, which have become a threat to humans. We are pleased to provide our compound library for screening. We hope new medicines will be discovered through this partnership to realize a world in which lives are no longer lost to drug-resistant bacteria.”
– Dr Kappei Tsukahara, Head of Tsukuba Research Laboraties, Eisai

Working in partnership to discover new treatments

As part of GARDP’s discovery and exploratory research efforts, Japanese pharmaceutical companies Daiichi Sankyo, Eisai and Takeda Pharmaceutical Company Limited have given GARDP access to their chemical libraries. The compounds, which have never been screened for antibacterial activity before, are being tested by Institut Pasteur Korea, an infectious disease-focused research institute.

 GARDP is also testing Calibr’s ReFRAME compound library and a Helmholtz-Institute for Pharmaceutical Research Saarland’s natural products library. Both are being tested at the University of Queensland’s Community for Open Antimicrobial Drug Discovery. Through screening these libraries, GARDP is working to identify novel compounds suitable for further optimization and development into new treatments for bacterial infections.

“The world needs global cooperative action to prevent a post-antibiotic era. This work, instigated by GARDP, is an active respone to this urgent global demand that connects Institut Pasteur Korea’s resource with the technology of global pharmaceutical companies.”
– Dr Wangshick Ryu, CEO of Institut Pasteur Korea

Over recent decades, with changing industry priorities, many antibiotic researchers have moved into different fields or retired, creating a discovery void. GARDP is working through its REVIVE programme to ensure critical knowledge is recovered and shared with a new generation of antibiotics researchers. Download the REVIVE programme snaphot for more information.

Download In Focus: Discovery & Exploratory Research>

Learn about GARDP’s serious bacterial infections in hospitalized adults programme.

Serious bacterial infections
We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.